Literature DB >> 27328919

TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data.

Liacine Bouaoun1, Dmitriy Sonkin2, Maude Ardin3, Monica Hollstein3,4, Graham Byrnes1, Jiri Zavadil3, Magali Olivier3.   

Abstract

TP53 gene mutations are one of the most frequent somatic events in cancer. The IARC TP53 Database (http://p53.iarc.fr) is a popular resource that compiles occurrence and phenotype data on TP53 germline and somatic variations linked to human cancer. The deluge of data coming from cancer genomic studies generates new data on TP53 variations and attracts a growing number of database users for the interpretation of TP53 variants. Here, we present the current contents and functionalities of the IARC TP53 Database and perform a systematic analysis of TP53 somatic mutation data extracted from this database and from genomic data repositories. This analysis showed that IARC has more TP53 somatic mutation data than genomic repositories (29,000 vs. 4,000). However, the more complete screening achieved by genomic studies highlighted some overlooked facts about TP53 mutations, such as the presence of a significant number of mutations occurring outside the DNA-binding domain in specific cancer types. We also provide an update on TP53 inherited variants including the ones that should be considered as neutral frequent variations. We thus provide an update of current knowledge on TP53 variations in human cancer as well as inform users on the efficient use of the IARC TP53 Database.
© 2016 WILEY PERIODICALS, INC.

Entities:  

Keywords:  TP53; annotations; cancer; germline variations; locus-specific database; mutation hotspots; somatic mutations

Mesh:

Substances:

Year:  2016        PMID: 27328919     DOI: 10.1002/humu.23035

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  261 in total

1.  Targeting phosphorylated p53 to elicit tumor-reactive T helper responses against head and neck squamous cell carcinoma.

Authors:  Kenzo Ohara; Takayuki Ohkuri; Takumi Kumai; Toshihiro Nagato; Yui Nozaki; Kei Ishibashi; Akemi Kosaka; Marino Nagata; Shohei Harabuchi; Mizuho Ohara; Kensuke Oikawa; Naoko Aoki; Yasuaki Harabuchi; Esteban Celis; Hiroya Kobayashi
Journal:  Oncoimmunology       Date:  2018-08-01       Impact factor: 8.110

2.  Association Between Genotype and Phenotype in Consecutive Unrelated Individuals With Retinoblastoma.

Authors:  Flore Salviat; Marion Gauthier-Villars; Matthieu Carton; Nathalie Cassoux; Livia Lumbroso-Le Rouic; Catherine Dehainault; Christine Levy; Lisa Golmard; Isabelle Aerts; François Doz; Fidéline Bonnet-Serrano; Stéphanie Hayek; Alexia Savignoni; Dominique Stoppa-Lyonnet; Claude Houdayer
Journal:  JAMA Ophthalmol       Date:  2020-08-01       Impact factor: 7.389

3.  High-resolution melting effectively pre-screens for TP53 mutations before direct sequencing in patients with diffuse glioma.

Authors:  Kiyotaka Saito; Kiyotaka Yokogami; Kazunari Maekawa; Yuichiro Sato; Shinji Yamashita; Fumitaka Matsumoto; Asako Mizuguchi; Hideo Takeshima
Journal:  Hum Cell       Date:  2021-01-17       Impact factor: 4.174

4.  Report of a bi-allelic truncating germline mutation in TP53.

Authors:  Natasha J Brown; Kanika Bhatia; Julie Teague; Susan M White; Patrick Lo; Jackie Challis; Victoria Beshay; Michael Sullivan; David Malkin; Jordan R Hansford
Journal:  Fam Cancer       Date:  2019-01       Impact factor: 2.375

5.  Transcriptional changes associated with in vivo growth of muscle-invasive bladder cancer cell lines in nude mice.

Authors:  Swathi Ramakrishnan; Wendy Huss; Barbara Foster; Joyce Ohm; Jianmin Wang; Gissou Azabdaftari; Kevin H Eng; Anna Woloszynska-Read
Journal:  Am J Clin Exp Urol       Date:  2018-06-15

6.  TP53 germline mutation testing in early-onset breast cancer: findings from a nationwide cohort.

Authors:  J J Bakhuizen; F B Hogervorst; M E Velthuizen; M W Ruijs; K van Engelen; T A van Os; J J Gille; M Collée; A M van den Ouweland; C J van Asperen; C M Kets; A R Mensenkamp; E M Leter; M J Blok; M M de Jong; M G Ausems
Journal:  Fam Cancer       Date:  2019-04       Impact factor: 2.375

7.  Higher-than-expected population prevalence of potentially pathogenic germline TP53 variants in individuals unselected for cancer history.

Authors:  Kelvin César de Andrade; Lisa Mirabello; Douglas R Stewart; Eric Karlins; Roelof Koster; Mingyi Wang; Susan M Gapstur; Mia M Gaudet; Neal D Freedman; Maria Teresa Landi; Nathanaël Lemonnier; Pierre Hainaut; Sharon A Savage; Maria Isabel Achatz
Journal:  Hum Mutat       Date:  2017-09-21       Impact factor: 4.878

8.  The first two confirmed sub-Saharan African families with germline TP53 mutations causing Li-Fraumeni syndrome.

Authors:  Shelley Macaulay; Quintin Clive Goodyear; Mia Kruger; Wenlong Chen; Fahmida Essop; Amanda Krause
Journal:  Fam Cancer       Date:  2018-10       Impact factor: 2.375

9.  Pathways of Metabolite-Related Damage to a Synthetic p53 Gene Exon 7 Oligonucleotide Using Magnetic Enzyme Bioreactor Beads and LC-MS/MS Sequencing.

Authors:  Spundana Malla; Karteek Kadimisetty; Di Jiang; Dharamainder Choudhary; James F Rusling
Journal:  Biochemistry       Date:  2018-05-23       Impact factor: 3.162

10.  Protein mimetic amyloid inhibitor potently abrogates cancer-associated mutant p53 aggregation and restores tumor suppressor function.

Authors:  L Palanikumar; Laura Karpauskaite; Mohamed Al-Sayegh; Ibrahim Chehade; Maheen Alam; Sarah Hassan; Debabrata Maity; Liaqat Ali; Mona Kalmouni; Yamanappa Hunashal; Jemil Ahmed; Tatiana Houhou; Shake Karapetyan; Zackary Falls; Ram Samudrala; Renu Pasricha; Gennaro Esposito; Ahmed J Afzal; Andrew D Hamilton; Sunil Kumar; Mazin Magzoub
Journal:  Nat Commun       Date:  2021-06-25       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.